Aurobindo will acquire pharmaceutical commercial infrastructure in Belgium, France, Germany, Italy, Spain, Portugal and The Netherlands from Actavis; including products, personnel, marketing authorizations and dossier licence rights. The two companies would also enter into a long-term strategic supply arrangement.

Since 2006 Aurobindo has been steadily expanding its presence in Europe through an increasing presence in Germany, Spain and the UK. The deal will complement existing Aurobindo European operations, adding capabilities in the seven countries, and will also complement its existing brands such as ‘Arrow Generiques’. The acquisition is expected to make Aurobindo one of the leading Indian pharmaceutical companies in Europe, with a top 10 position in several key markets.

Aurobindo is expected to pay around Euros 30 million for the businesses. Although they are currently loss-making Aurobindo believes that the company ‘is well positioned to improve the profitability of the businesses by combining them with its integrated large scale India-based manufacturing operations and existing European infrastructure’.

The companies ‘believe that the value created by the commercial operations in these seven markets will be better maximized by Aurobindo, which will gain scale, additional products and enhanced competitive market share position as a result of this transaction’. The transaction will also permit Actavis to focus management time and resources to support accelerated investment in driving faster growth of other markets including Central and Eastern Europe and Southeast Asia.

Related articles

Actavis submits ANDAs for two more generics

Aurobindo forms generics joint venture with Russia’s Diod

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.